Several emerging serologic biomarkers have been applied in clinical use for early lung cancer screening and diagnosis such as carcinoembryonic antigen (CEA) and serum cytokeratin 19 fragments (CYFRA 21‐1), which can be analysed conveniently and economically.45 This evidence concerns the gene CEACAM5 and lung carcinoma.